| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Trump's healthcare plans under contention after Democrats' midterm landslide | ||
| 12:46 | Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn | ||
| 12:46 | AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera | ||
| 11:46 | GEBRO and Spektus sign collaboration for ActraFlex | ||
| 10:46 | FDA to review uniQure's BLA for Huntington's gene therapy | ||
| Di | FDA calls for stronger potency upkeep in CGT manufacturing | ||
| Di | AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals | ||
| Di | Lonza to acquire five US manufacturing sites from Merck KGaA | ||
| Di | Bavarian Nordic secures four-year UK vaccine supply deal | ||
| Mo | Fresenius and WuXi team up in 37-strong biosimilar development deal | ||
| Mo | Pelthos and Castle Creek plan merger to target skin diseases | ||
| Mo | Inovio's Voceryq receives FDA accelerated approval for RRP | ||
| Fr | Casgevy gains UK label expansion for younger patient population | ||
| Fr | Eli Lilly's tirzepatide outperforms big pharma companies in Q3 | ||
| Fr | Glenmark opens Allentown distribution hub in US | ||
| Fr | Dren Bio raises $350m for dibotatug clinical development | ||
| Do | RFK Jr backs compounding of six unapproved peptides in new policy | ||
| Do | UK Budget light on life sciences but more doors open for biotech startups | ||
| Do | Enthorin and Rumi sign agreement for FXS therapy | ||
| Do | Formation Bio launches $600m drug development fund | ||
| 28.10. | Ferring bets on Gameto's reproductive health solution through $1.38bn takeover | ||
| 28.10. | Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal | ||
| 28.10. | FDA grants orphan drug status to Octant's OCT-980 for RP | ||
| 28.10. | Arrowhead gains UK marketing authorisation for Redemplo | ||
| 28.10. | Anthropic plots IPO amid ongoing foray into drug development |